BIOMX PHGE 深 沪
等待开盘 11-26 09:30:00 美东时间
5.78
+0.295
+5.37%
华盛通- 最 高5.95
- 今 开5.49
- 成交量 12.35万股
- 最 低 4.89
- 昨 收 5.4853
- 总市值 1.53亿
- 52周最高 5.95
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.245
- 委 比 0.00%
- 总股本 2655.49万
- 历史最高 119.00
- 量 比 0.13
- 振 幅 19.32%
- 历史最低 0.245
- 每 手 1
- 风险率 2.57%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 安捷伦科技、Keysight、先科电子获多家大行上调目标价；摩根大通下调亿航智能评级至"中性"，目标价下调至13美元
今日重点评级关注：HC Wainwright & Co.：维持BiomX"买入"评级，目标价从15美元升至26美元；Clear Street：维持Diversified Energy"买入"评级，目标价从23美元升至25美元
今天 10:07
BiomX Updates on Phase 2b Study for BX004
BiomX ( ($PHGE) ) has issued an announcement. On November 25, 2025, BiomX Inc. ...
今天 06:26
HC Wainwright & Co. Maintains Buy on BiomX, Raises Price Target to $26
HC Wainwright & Co. analyst Joseph Pantginis maintains BiomX (AMEX:PHGE) with a Buy and raises the price target from $15 to $26.
11-25 19:54
BiomX announces 1-for-19 reverse stock split
BiomX (PHGE) on Friday said that it will implement a one-for-nineteen reverse split of its common shares, effective when trading opens on November 25 on a split-adjusted basis. The company said the mo...
11-15 05:37
BiomX Announces 1-For-19 Reverse Stock Split, Effective Nov. 25
BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that it intends to
11-15 05:35
BiomX Q3 EPS $0.29 Beats $(0.32) Estimate
BiomX (AMEX:PHGE) reported quarterly earnings of $0.29 per share which beat the analyst consensus estimate of $(0.32) by 190.63 percent. This is a 193.55 percent increase over losses of $(0.31) per share from the same
11-12 20:32
Earnings Scheduled For November 12, 2025
Companies Reporting Before The Bell • Hudbay Minerals (NYSE:HBM) is projected t...
11-12 19:11
BiomX Reports Third Quarter 2025 Financial Results and Provides Program Updates
BiomX Inc. announced Q3 2025 financial results and updates on its phage therapy pipeline. The company received positive FDA feedback for BX004, a phage cocktail for cystic fibrosis patients with P. aeruginosa, and anticipates resolving a clinical hold soon. For BX011, targeting S. aureus in diabetic foot infections, the FDA confirmed a clear clinical pathway. The company's cash balance decreased to $8.1 million, with R&D expenses down 16.8% to $6...
11-12 12:30
Earnings Preview For BiomX
BiomX (AMEX:PHGE) is set to give its latest quarterly earnings report on Wednes...
11-12 01:12
BiomX Receives FDA Support To Advance BX011 Phage Therapy For Diabetic Foot Infections
BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that it has received positive
11-04 21:41
